MedTrace Logo

PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

NCT03120000 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-11-16

No results posted yet for this study

Summary

An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).

Conditions

Interventions

DRUG

PQR309

Oral PQR309, 80mg or 60mg daily or intermittent dosing

Sponsors & Collaborators

  • PIQUR Therapeutics AG

    lead INDUSTRY

Principal Investigators

  • Augusti Alentorn, MD · Hospital Pitié-Sâlpetrière, Paris

  • Olivier-Louis Chinot, Prof · Aix Marseilles Université

  • Luc Taillandier, Prof · Service de neuro-oncology CHRU de Nancy

  • Phililippe Agape, MD · Hématologie, Département d'oncologie médicale,Saint_Herblain

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03120000 on ClinicalTrials.gov